{"id":28179,"date":"2022-06-30T13:52:48","date_gmt":"2022-06-30T13:52:48","guid":{"rendered":"https:\/\/ogkologos.com\/2022-asco-annual-meeting-research-round-up-advances-in-treating-genitourinary-cancers\/"},"modified":"2024-11-03T15:13:36","modified_gmt":"2024-11-03T15:13:36","slug":"2022-asco-annual-meeting-research-round-up-advances-in-treating-genitourinary-cancers","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/2022-asco-annual-meeting-research-round-up-advances-in-treating-genitourinary-cancers\/","title":{"rendered":"2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary Cancers"},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/2022-gu-webinar-fb.png\" class=\"ff-og-image-inserted\"><\/div>\n<p>In the annual Research Round Up series, Cancer.Net Editorial Board members answer the questions, \u201cWhat was the most exciting or practice-changing research in your field presented at the 2022 ASCO Annual Meeting or the 2022 Genitourinary Cancers Symposium, and what does it mean for people with cancer?\u201d<\/p>\n<p>In this webinar, Cancer.Net Specialty Editors Neeraj Agarwal, MD; Timothy Gilligan, MD, FASCO; Petros Grivas, MD, PhD; and Tian Zhang, MD, discuss new and ongoing research in&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/31382\">prostate cancer<\/a>, <a href=\"https:\/\/www.cancer.net\/node\/31375\">testicular cancer<\/a>,&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/31330\">bladder cancer<\/a>,&nbsp;and <a href=\"https:\/\/www.cancer.net\/node\/31256\">kidney cancer<\/a>.<\/p>\n<ul readability=\"19.38930976431\">\n<li readability=\"3.7418300653595\">\n<p>An update from the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.5000\" target=\"_blank\" rel=\"noopener\">phase 2 TheraP clinical trial<\/a>, which was studying whether <a href=\"https:\/\/www.cancer.net\/node\/41713\">lutetium-177-PSMA-617 (<sup>177<\/sup>Lu-PSMA-617 or LuPSMA)<\/a>, a type of targeted radiation treatment, could help some people with metastatic castration-resistant prostate cancer that grew after treatment with chemotherapy live longer. [3:38]<\/p>\n<\/li>\n<li readability=\"3.2271186440678\">\n<p>An update from the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.17_suppl.LBA5004\" target=\"_blank\" rel=\"noopener\">phase 3 ENZAMET clinical trial<\/a>, which was evaluating whether adding enzalutamide (Xtandi), a type of hormonal therapy called an <a href=\"https:\/\/www.cancer.net\/node\/19569\">androgen receptor inhibitor<\/a>, to androgen-deprivation therapy could help people with metastatic hormone-sensitive prostate cancer live longer. [6:44]<\/p>\n<\/li>\n<li readability=\"1.6969696969697\">\n<p>Results from a <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.5008\" target=\"_blank\" rel=\"noopener\">national cohort study out of Norway<\/a> that evaluated how common it is for people with testicular cancer to experience a late recurrence, which is when the cancer comes back 2 to 5 years or more after treatment. [11:00]<\/p>\n<\/li>\n<li readability=\"2.6666666666667\">\n<p>Results from <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.5032\" target=\"_blank\" rel=\"noopener\">a study<\/a> testing whether high-dose chemotherapy is a good option for people with non-seminoma&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/31298\">germ cell tumors<\/a> of the mediastinum, or center of the chest, that return after chemotherapy. [14:35]<\/p>\n<\/li>\n<li readability=\"1.6549295774648\">\n<p>The final results from the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.4508\" target=\"_blank\" rel=\"noopener\">phase 2\/3 QUILT-3.032 clinical trial<\/a>, which was studying whether adding the <a href=\"https:\/\/www.cancer.net\/node\/24726\">immunotherapy<\/a> N-803 to standard immunotherapy helped shrink the tumors of people with non-muscle-invasive bladder cancer and helped them avoid surgery to remove the bladder. [17:46]<\/p>\n<\/li>\n<li readability=\"0\">\n<p>Findings from <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.4577\" target=\"_blank\" rel=\"noopener\">a survey<\/a> being used to develop criteria to help oncologists identify which people with metastatic urothelial cancer should avoid platinum-based chemotherapy. [20:57]<\/p>\n<\/li>\n<li readability=\"1.6978417266187\">\n<p>Long-term results from the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.6_suppl.487\" target=\"_blank\" rel=\"noopener\">phase 3 JAVELIN Bladder 100 clinical trial<\/a>, which was evaluating whether people with advanced urothelial cancer should receive maintenance therapy with the immunotherapy avelumab (Bavencio) following treatment with platinum-based chemotherapy. [24:18]<\/p>\n<\/li>\n<li readability=\"1.6051502145923\">\n<p>Results from the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.17_suppl.LBA4500\" target=\"_blank\" rel=\"noopener\">phase 3 EVEREST clinical trial<\/a>, which was investigating whether the <a href=\"https:\/\/www.cancer.net\/node\/24729\">targeted therapy<\/a> drug everolimus (Afinitor) could delay or prevent recurrence in people with renal cell carcinoma who have received surgery. [27:16]<\/p>\n<\/li>\n<li readability=\"2.656050955414\">\n<p>An analysis of the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.4501\" target=\"_blank\" rel=\"noopener\">phase 3 CheckMate 9ER clinical trial<\/a>, which was studying whether initial treatment with the targeted therapy combination cabozantinib (Cabometyx) and nivolumab (Opdivo) delays cancer growth longer than the targeted therapy sunitinib (Sutent) in people with advanced renal cell carcinoma. [29:52]<\/p>\n<\/li>\n<li readability=\"-1\">\n<p>A Q&amp;A with the expert panelists. [32:12]<\/p>\n<\/li>\n<\/ul>\n<p>Dr. Agarwal is the senior director of clinical research innovation at the Huntsman Cancer Institute at the University of Utah and a 2022&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/40651\">Cancer.Net Specialty Editor for Genitourinary Cancers<\/a>. Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a 2022&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/30276\">Cancer.Net Specialty Editor for Genitourinary Cancers<\/a>. Dr. Grivas is a medical oncologist at the Seattle Cancer Care Alliance, the clinical director of the Genitourinary Cancers Program at the University of Washington, and a 2022&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/40701\">Cancer.Net Specialty Editor for Genitourinary Cancers<\/a>. Dr. Zhang is an associate professor of internal medicine at the University of Texas Southwestern Medical Center, a medical oncologist at the Harold C. Simmons Comprehensive Cancer Center, and a 2022&nbsp;<a href=\"https:\/\/www.cancer.net\/node\/40706\">Cancer.Net Specialty Editor for Genitourinary Cancers<\/a>.<\/p>\n<p>Disclosure information for this webinar\u2019s speakers can be found in their individual biographies, which are linked in the paragraph above.<\/p>\n<p><b><i>Was this podcast useful?<\/i><\/b> <i>Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A <a href=\"https:\/\/www.cancer.net\/node\/42054\">transcript<\/a> is also available. For more information, visit the <\/i><a href=\"http:\/\/www.cancer.net\/blog\/podcasts\"><i>Cancer.Net podcast page<\/i><\/a><i><span>.<\/span><\/i><\/p>\n<p><i>Cancer.Net podcasts are edited for length and content. <\/i><\/p>\n<p><a href=\"https:\/\/www.cancer.net\/blog\/2022-06\/2022-asco-annual-meeting-research-round-advances-treating-genitourinary-cancers\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the annual Research Round Up series, Cancer.Net Editorial Board members answer the questions, \u201cWhat was the most exciting or practice-changing research in your field presented at the 2022 ASCO Annual Meeting or the 2022 Genitourinary Cancers Symposium, and what does it mean for people with cancer?\u201d In this webinar, Cancer.Net Specialty Editors Neeraj Agarwal, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-28179","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=28179"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28179\/revisions"}],"predecessor-version":[{"id":43278,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28179\/revisions\/43278"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=28179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=28179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=28179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}